Pityriasis rubra pilaris (PRP) includes a spectrum of rare chronic inflammatory disorders with papulosquamous eruptions of unknown cause. Different etiologies have been proposed such as vitamin A metabolism dysfunction, association with autoimmune disorders, infection or malignancies. However, PRP seems to be a polygenic skin disorder. Classical systemic treatment is empirical and includes retinoids and methotrexate; however, only few series on treatments exist. Recently there has been an increasing number of reports documenting that new biologicals and in particular TNF-α blockers are safe and effective.

Keywords:
Pityriasis rubra pilaris, Biological agents, Tumor necrosis factor
1.
Griffiths WAD: Pityriasis rubra pilaris: the problem of its classification. J Am Acad Dermatol 1992;26:140–142.
2.
Besnier E: Observations pour servir à l’histoire clinique du pityriasis rubra pilaire. Ann Dermatol Syphiligr (Paris) 1889;10(ser 2):253–287.
3.
Artik S, Kuhn A, Neumann NJ, Ruzicka T, Megahed M: Pityriasis rubra pilaris. Hautarzt 2004;55:980–983.
4.
Loewenthal LJA: A new cutaneous manifestation in the syndrome of vitamin A deficiency. Arch Dermatol Syphilol 1933;28:700–708.
5.
Finzi AF, Altomare G, Bergamaschini L, Tucci A: Pitiyriasis rubra pilaris and retionol-binding protein. Br J Dermatol 1981;104:253–256.
6.
Mohrenschlager M, Abeck D: Further clinical evidence for involvement of bacterial superantigens in juvenile pityriasis rubra pilaris (PRP): report of two cases. Pediatr Dermatol 2002;19:569.
7.
Yaniv R, Barzilai A, Trau H: Pityriasis rubra pilaris exacerbated by ultraviolet B phototherapy. Dermatology 1994;189:313.
8.
Kawara S, Miyake M, Oiso N, Kawada A: Pityriasis rubra pilaris with preceding cytomegalovirus infection. Dermatology 2009;219:350–352.
9.
Reinhardt LA, Rosen T: Pityriasis rubra pilaris as the initial manifestation of leukemia. Cutis 1983;31:100–102.
10.
Burger B, Spoerri I, Schubert M, Has C, Itin PH: Description of the natural course and clinical manifestations of ichthyosis with confetti caused by a novel KRT10 mutation. Br J Dermatol 2011;166:434–439.
11.
Gemmeke A, Schönlebe J, Koch A, Wollina U: Pityriasis rubra pilaris – a retrospective single center analysis over eight years. J Dtsch Dermatol Ges 2010;8:439–444.
12.
Miralles ES, Núñez M, De Las Heras ME, Pérez B, Moreno R, Ledo A: Pityriasis rubra pilaris and human immunodeficiency virus infection. Br J Dermatol 1995;133:990–993.
13.
Soeprono FF: Histologic criteria for the diagnosis of pityriasis rubra pilaris. Am J Dermatopathol 1986;8:277–283.
14.
Cowen P, O’Keefe R: Pityriasis rubra pilaris and focal acantholytic dyskeratosis. Australas J Dermatol 1997;38:40–41.
15.
Porter D, Shuster S: Epidermal renewal and amino acids in psoriasis and pityriasis rubra pilaris. Arch Dermatol 1968;98:339–343.
16.
Griffiths WAD, Pieris S: Pityriasis rubra pilaris – an autoradiographic study. Br J Dermatol 1982;107:665–667.
17.
Niemi KM, Kousa M, Storgards K, Karvonen J: Pityriasis rubra pilaris. A clinicopathological study with a special reference to autoradiography and histocompatibility antigens. Dermatologica 1976;152:109–118.
18.
Vanderhooft SL, Francis JS, Holbrook KA, et al: Familial pityriasis rubra pilaris. Arch Dermatol 1995;131:448–453.
19.
Randle HW, Diaz-Perez JL, Winkelmann RK: Toxic doses of vitamin A for pityriasis rubra pilaris. Arch Dermatol 1980;116:888–892.
20.
Griffiths WAD: Vitamin A and pityriasis rubra pilaris (letter). J Am Acad Dermatol 1982;7:555.
21.
Albert MR, Mackool BT: Pityriasis rubra pilaris. Int J Dermatol 1999;38:1–11.
22.
Betloch K, Ramfin R, Silvestre JF, Carneto L, Albares MP, Baňuls J: Acute juvenile pityriasis rubra pilaris: a superantigen mediated disease? Pediatr Dermatol 2001;18:411–414.
23.
Müller H, Gattringer C, Zelger B, Höpfl R, Eisendle K: Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: case report and review of the literature on biologic therapy. J Am Acad Dermatol 2008;59(suppl):65–70.
24.
Drosou A, Kirsner RS, Welsh E, Sullivan TP, Kerdel FA: Use of infliximab, an anti-tumor necrosis factor alpha antibody, for inflammatory dermatoses. J Cutan Med Surg 2003;7:382–386.
25.
Manoharan S, White S, Gumparthy K: Successful treatment of type I adult-onset pityriasis rubra pilaris with infliximab. Australas J Dermatol 2006;47:124–129.
26.
Ruiz-Genao DP, Lopez-Estebaranz JL, Naz-Villalba E, Gamo-Villegas R, Calzado-Villarreal L, Pinedo-Moraleda F: Pityriasis rubra pilaris successfully treated with infliximab. Acta Derm Venereol 2007;87:552–553.
27.
Liao WC, Mutasim DF: Infliximab for the treatment of adult-onset pityriasis rubra pilaris. Arch Dermatol 2005;141:423–425.
28.
Lu R, George SJ, Hsu S: Pityriasis rubra pilaris: failure of combination treatment with acitretin and infliximab. Dermatol Online J 2006;30:12–18.
29.
Garcovich S, Di Giampetruzzi AR, Antonelli G, Garcovich A, Didona B: Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: a case series. J Eur Acad Dermatol Venereol 2010;24:881–884.
30.
Klein A, Szeimies RM, Landthaler M, Karrer S: Exacerbation of pityriasis rubra pilaris under efalizumab therapy. Dermatology 2007;215:72–75.
31.
Davis KF, Wu JJ, Murase JE, Rosenberg FR, Sorenson EP, Meshkinpour A: Clinical improvement of pityriasis rubra pilaris with combination etanercept and acitretin therapy. Arch Dermatol 2007;143:1597–1599.
32.
Walling HW, Swick BL: Pityriasis rubra pilaris responding rapidly to adalimumab. Arch Dermatol 2009;145:99–101.
33.
Schreml S, Zeller V, Babilas P, Karrer S, Landthaler M, Szeimies RM: Pityriasis rubra pilaris successfully treated with adalimumab. Clin Exp Dermatol 2010;35:792–793.
34.
Guedes R, Leite L: Therapeutic hotline. Treatment of pityriasis rubra pilaris with etanercept. Dermatol Ther 2011;24:285–286.
35.
Vasher M, Smithberger E, Lien MH, Fenske NA: Familial pityriasis rubra pilaris: report of a family and therapeutic response to etanercept. J Drugs Dermatol 2010;9:844–850.
36.
Zhang YH, Zhou Y, Ball N, Su MW, Xu JH, Zheng ZZ: Type I pityriasis rubra pilaris: upregulation of tumor necrosis factor alpha and response to adalimumab therapy. J Cutan Med Surg 2010;14:185–188.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.